argipressin--des-glynh2(9)- and Cognition-Disorders

argipressin--des-glynh2(9)- has been researched along with Cognition-Disorders* in 2 studies

Trials

1 trial(s) available for argipressin--des-glynh2(9)- and Cognition-Disorders

ArticleYear
A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma.
    Neurology, 1993, Volume: 43, Issue:1

    Recent evidence suggests that the vasopressin analogue desglycinamide-arginine8-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched-pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.

    Topics: Adolescent; Adult; Aged; Arginine Vasopressin; Cognition Disorders; Craniocerebral Trauma; Double-Blind Method; Female; Humans; Male; Middle Aged

1993

Other Studies

1 other study(ies) available for argipressin--des-glynh2(9)- and Cognition-Disorders

ArticleYear
Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in cognitively impaired patients.
    Psychopharmacology bulletin, 1982, Volume: 18, Issue:4

    Topics: Aged; Arginine Vasopressin; Cognition Disorders; Humans; Male; Middle Aged

1982